|
|
| | 4-[N-(4-Carboxybutyl)-N-[2-[2-[4-(2-phenylethyl)benzyloxy]phenyl]ethyl]aMinoMethyl]benzoic acid Basic information |
| | 4-[N-(4-Carboxybutyl)-N-[2-[2-[4-(2-phenylethyl)benzyloxy]phenyl]ethyl]aMinoMethyl]benzoic acid Chemical Properties |
| storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | Soluble in DMSO | | form | Powder |
| | 4-[N-(4-Carboxybutyl)-N-[2-[2-[4-(2-phenylethyl)benzyloxy]phenyl]ethyl]aMinoMethyl]benzoic acid Usage And Synthesis |
| Definition | ChEBI: Cinaciguat is a benzoic acid that is 4-(aminomethyl)benzoic acid in which the amino group is substituted by 4-carboxybutyl and 2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl groups. It is a soluble guanylate cyclase activator, used for the treatment of acute decompensated heart failure. It has a role as a vasodilator agent, a soluble guanylate cyclase activator and an antihypertensive agent. It is a member of benzoic acids, a tertiary amino compound, an aromatic ether and a dicarboxylic acid. | | Biological Activity | Cinaciguat hydrochloride is a nitric oxide-independent guanylate cyclase (GC) activator with a Kd of 3.2 nM. | | in vitro | Cinaciguat (10 μM) significantly enhances intracellular cGMP generation. It does not dose-dependent effects on cell contraction and calcium transients. < /div> | | in vivo | Cinaciguat (10 mg/kg/day, po) treatment in diabetic rats does not influence blood glucose levels, but leads to attenuated water intake. It treatment alleviates diabetes mellitus related oxidative stress, protects against DM related alteration of the NO-sGC-cGMP-PKG signalling, and alleviates DM related myocardium hypertrophy and apoptosis. Cinaciguat (1-10-100 nM) induces concentration-dependent relaxations in strips from both WT and apo-sGC mice, but does not have any effect on phasic activity induced by PGF 2α in WT or apo-sGC strips. | | target | sGC |
| | 4-[N-(4-Carboxybutyl)-N-[2-[2-[4-(2-phenylethyl)benzyloxy]phenyl]ethyl]aMinoMethyl]benzoic acid Preparation Products And Raw materials |
|